Cantor Fitzgerald Reiterates Overweight on Vincerx Pharma, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Li Watsek has reiterated an Overweight rating on Vincerx Pharma (NASDAQ:VINC) and maintained a $5 price target.
September 07, 2023 | 4:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vincerx Pharma's stock rating has been reiterated as Overweight by Cantor Fitzgerald, with a maintained price target of $5.
The reiteration of an Overweight rating by Cantor Fitzgerald indicates a positive outlook for Vincerx Pharma. This could potentially lead to an increase in the stock's price in the short term. The maintained price target of $5 also suggests that the analyst believes the stock is currently undervalued.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100